Abstract Body

Background

Recombinant broadly neutralizing antibodies (bNAbs) are a promising therapeutic approach against HIV but may face manufacturing challenges. mRNA-encoded bNAbs (RibobNAbs) provide an alternative mode of delivery, characterized by rapid production and in vivo assembly, circumventing the challenges of recombinant antibody production. As proof of concept, we developed bNAb PGT121, featuring half-life extending LS mutations, encoded in mRNA formulated in lipid nanoparticles (RiboPGT121-LS). The aim of this study was to characterize RiboPGT121-LS in vitro and assess its pharmacokinetics (PK), tolerability, and functionality in non-human primates (NHPs).

Methods

Expression and assembly of RiboPGT121-LS were confirmed via ELISA and western blot. Target binding affinity and antiviral efficacy were assessed using SOSIP-ELISA, biolayer interferometry, and pseudovirus neutralization assay (pVNT). Tolerability and PK of RiboPGT121-LS were investigated in NHPs after single dose intravenous (IV) and intramuscular (IM) administration and compared to recombinant antibody IV. Anti-drug antibodies (ADA) were quantified using a three-tiered approach, and RibobNAb functionality from serum samples was assessed via pVNT.

Results

RiboPGT121-LS was expressed and correctly assembled in vitro, bound SOSIP at picomolar affinity and retained viral neutralization of recombinant PGT121-LS. In NHPs, IV administration was well-tolerated without ADA formation. RiboPGT121-LS half-life and neutralizing activity post in vivo expression closely matched those of recombinant PGT121-LS. Similarly, IM administration resulted in expression of functional antibodies, but with lower bioavailability, correlating with ADA development. Our NHP dataset indicated that the RibobNAb platform can maintain therapeutic antibody titers for an extended period of time.

Conclusions

Leveraging mRNA technology, we generated functional RiboPGT121-LS, which retained high target binding affinity and potent antiviral neutralization in vitro. Following IV administration in NHPs, RiboPGT121-LS was well-tolerated and elicited functional antibodies, as well as a PK comparable to recombinant protein. This study highlights the RibobNAb platform as a promising alternative for HIV bNAb delivery.